If you are about to unleash a revolutionary slumber enhancement and cold relief concept on the U.S. market there is probably not a better launching pad than the 32nd annual Sleep 2019 Conference, which is coming up in June in Texas.
Organized by the American Academy of Sleep Medicine, the conference is shifting this year’s convention location from the north east of the country to San Antonio, home of the Alamo and where the siesta is celebrated.
Rhinomed CEO Michael Johnson considers it an appropriate forum for the company’s newest products, Pronto Sleep and Pronto Clear, the first platforms to showcase its new rechargeable, dual action vapor release technology.
Following extensive product development and consumer testing the company launched the technology range in prototype form at a major trade show in Chicago in February. The positive response resulted in a swift move into production.
It has been an immediate hit having received an initial purchase order for the Pronto Sleep product for over 2800 packs across 900 stores from one of the largest stockists of its cornerstone Mute, anti-snoring device.
Shipment of the product will begin at the end of May and it should be on U.S. drug store shelves within three to four months. Sales could be reflected in the revenue line as early as the December 2019 quarter.
The Pronto Clear nasal decongestant product will be released later in 2019 to coincide with the North American cough, cold and flu season.
The new products utilize Rhinomed’s trademarked Airstream vapor release system which manages the supply of a formulation into the nasal airstream over a set period of time. It combines the use of the technology with the Mute’s stenting action.
The company has also developed a system which recharges the device, allowing it to be reused a set number of times.
The successful introduction of the new product range sets the stage for Rhinomed to move further into the formulation delivery market including via its tie-up with Columbia Care, the leading provider of medicinal cannabis products in the U.S.
Michael Johnson said: “Rhinomed is delivering on its potential as a world leading innovator in the nasal, respiratory, sleep and drug delivery markets.
“Mute has given the company an exceptional foothold into the retail pharmacy market in the U.S.
“The Pronto range is the culmination of an exciting product development program but is also just the beginning of our drug delivery program. We have many more iterations in the pipeline including our work with Columbia Care.”
Hasta la Vista, baby!